59 related articles for article (PubMed ID: 7950171)
1. Adverse events of erythropoietin in long-term and in acute/short-term treatment.
Singbartl G
Clin Investig; 1994; 72(6 Suppl):S36-43. PubMed ID: 7950171
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
3. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. [The present possibilities for routine use of blood-saving measures from the anesthesiologic point of view--theoretical bases and clinical practice. IV: Supportive administration of erythropoietin and iron].
Singbartl G
Anaesthesiol Reanim; 1994; 19 Suppl():25-31. PubMed ID: 8148015
[TBL] [Abstract][Full Text] [Related]
6. Anemia in the critically ill.
Shander A
Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
8. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
9. [Retrospective studies and prospects of therapy for hypertension].
Maisch B; Brilla C; Kruse T; Noll B; Bethge C
Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
[TBL] [Abstract][Full Text] [Related]
10. [-Anticoagulant drugs-].
Gulba DC
Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
[TBL] [Abstract][Full Text] [Related]
11. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
13. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
14. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: light and shade.
Berardi D; Agati L
Minerva Cardioangiol; 2012 Apr; 60(2):227-36. PubMed ID: 22495171
[TBL] [Abstract][Full Text] [Related]
16. The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.
Lin TY; Lai YF; Chen YH; Lu DW
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555679
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin Interacts with Specific S100 Proteins.
Kazakov AS; Deryusheva EI; Sokolov AS; Permyakova ME; Litus EA; Rastrygina VA; Uversky VN; Permyakov EA; Permyakov SE
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053268
[TBL] [Abstract][Full Text] [Related]
18. Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice.
Ustyuzhanina NE; Anisimova NY; Bilan MI; Donenko FV; Morozevich GE; Yashunskiy DV; Usov AI; Siminyan NG; Kirgisov KI; Varfolomeeva SR; Kiselevskiy MV; Nifantiev NE
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832856
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin Administration for Anemia Due to Chronic Kidney Disease - Subcutaneous OR Intravenous, What Do We Know So Far?
Shahab MH; Saifullah Khan S
Cureus; 2020 Sep; 12(9):e10358. PubMed ID: 33062481
[TBL] [Abstract][Full Text] [Related]
20. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
